ADXS NEO
Alternative Names: ADXS-NEO; Neoepitope-based immunotherapies - Ayala PharmaceuticalsLatest Information Update: 23 Jan 2023
At a glance
- Originator Advaxis; Memorial Sloan-Kettering Cancer Center
- Developer Amgen; Ayala Pharmaceuticals; Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; Cancer vaccines; Gene therapies; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bladder cancer; Cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer
Most Recent Events
- 19 Jan 2023 Advaxis has merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals
- 28 Jul 2022 No recent reports of development identified for phase-I development in Bladder-cancer(Late-stage disease, Metastatic disease, Monotherapy) in USA (Parenteral)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Malignant-melanoma(Late-stage disease, Metastatic disease, Monotherapy) in USA (Parenteral)